WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development

    OAKLAND, Calif., Sept. 6 /CNW/ -- (Nasdaq:   WHRT, TSX: WHT) World Heart
Corporation (WorldHeart), a developer of mechanical circulatory support
systems, announced successful completion of the first multi-day animal study
of a miniaturized, pediatric, ventricular assist device (VAD).  The
PediaFlow(TM), developed by a National Institutes of Health-funded consortium
including WorldHeart, is expected to be the platform for a future minimally
invasive adult VAD, intended to meet a large clinical need for earlier-stage
heart failure patients.
    The animal implant was performed by Peter Wearden, M.D., Ph.D., pediatric
cardiac surgeon at the Children's Hospital of Pittsburgh.  The six-day study,
at the University of Pittsburgh McGowan Institute, focused on hemodynamic
performance and biocompatibility under physiologic conditions.  The device
provided uninterrupted support and met all design targets.  Biocompatibility
was demonstrated, with no indications of blood damage or clotting.
    Dr. Harvey Borovetz, the Robert L. Hardesty Professor of Surgery,
Chairman of Bioengineering at the University of Pittsburgh and Principal
Investigator of the associated NIH PediaFlow development contract, remarked
that, "With the success of the recent in vivo experiments, we are encouraged
to begin 30-day animal implants, focusing again on pump performance and
    Mr. Jal Jassawalla, WorldHeart's President and CEO, commented, "The
positive results of the initial in vivo implants highlight the potential
benefits of WorldHeart's MagLev(TM) technology.  We are excited that this
technology, first embodied in the Levacor(TM) VAD, is being extended to the
pediatric VAD and then potentially to a WorldHeart minimally invasive adult
VAD."  The latter, providing partial circulatory support, would serve a broad
population with less advanced heart failure.  Such a device would complement
WorldHeart's Levacor VAD, which is intended to provide a greater degree of
support to patients in advanced heart failure.  A U.S. feasibility-phase
bridge-to-transplant study of the Levacor VAD is planned to begin in late 2007
or early 2008.  WorldHeart has been interacting with the FDA regarding final
pre-clinical qualification testing and the clinical protocol for the upcoming
    About the Levacor VAD
    The Levacor is a next-generation rotary VAD.  It is the only bearingless,
fully magnetically levitated implantable centrifugal rotary pump with clinical
experience.  An advanced, continuous-flow pump, the Levacor VAD uses magnetic
levitation to fully suspend the spinning rotor, its only moving part, inside a
compact housing.  The proprietary levitation technology employs a unique
arrangement of magnetics expected to provide optimal system simplicity and
reliability.  In contrast to pumps with blood-immersed mechanical or
hydrodynamic bearings, full magnetic levitation eliminates wear within the
pump as well as eliminates dependence on blood properties for rotor
suspension.  It is expected to provide improved blood compatibility by
allowing greater clearances around the rotor and more idealized flow patterns
across a wider range of operation.  The Levacor VAD has been designed with a
high safety profile and robust range of operation to address the needs of
current and future heart failure patients.
    About the PediaFlow VAD
    The PediaFlow VAD is an implantable, magnetically levitated rotary blood
pump based on WorldHeart's proprietary MagLev technology.  Configured for
pediatric use, the PediaFlow VAD is being developed to provide medium-term (<
1 year) implantable circulatory support to patients from birth to 2 years of
age with congenital or acquired heart disease.  PediaFlow design and
development is funded by the National Institutes of Health and involves a
consortium that encompasses the University of Pittsburgh, Children's Hospital
of Pittsburgh, the University of Pittsburgh Medical Center, the Artificial
Heart Program at LDS Hospital in Salt Lake City, Primary Children's Medical
Center in Salt Lake City, LaunchPoint Technologies, Carnegie-Mellon University
and WorldHeart.
    About WorldHeart
    WorldHeart is a developer of mechanical circulatory support systems with
leading next-generation technologies.  The Company is headquartered in
Oakland, California, with additional facilities in Salt Lake City, Utah and
Herkenbosch, The Netherlands. WorldHeart's registered office is Ottawa,
Ontario, Canada.
    Any forward-looking statements in this release are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995
and include statements regarding the Company's expectations with respect to
the Company's future development plans for its next-generation Levacor VAD and
PediaFlow VAD, including the timing and scope of clinical trials, the
potential scope of use and clinical benefits of these devices, as well as,
other statements that can be identified by the use of forward-looking
language, such as "believes," "feels," "expects," "may," "will," "should,"
"seeks," "plans," "anticipates," or "intends" or the negative of those terms,
or by discussions of strategy or intentions.  Investors are cautioned that all
forward-looking statements involve risk and uncertainties, which could cause
actual results to differ materially from those expressed or implied by the
forward-looking statements, including without limitation: delays in
development, preclinical qualification and regulatory approvals, and clinical
trials; Destination Therapy adoption rate for VADs; competition, the need for
additional financing; and other risks detailed in the Company's filings with
the United States Securities and Exchange Commission, including its Annual
Report on Form 10-KSB for the year ended December 31, 2006, as amended.

For further information:

For further information: Mr. David Pellone, +1-510-563-4775, or Ms.
Peggy  Allman, +1-510-563-4721, both of World Heart Corporation; or Mr.
Stephen Laird  +1-203-341-0214 of Genesis Select Corporation, for World Heart
Corporation Web Site:        

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890